

Risk factors distribution and cardiovascular disease prevalence in the Italian population: The CHECK study

Elena Tragni¹, Alessandro Filippi², Manuela Casula¹, Giampiero Favato³, Ovidio Brignoli², Claudio Cricelli², Andrea Poli¹, Alberico L. Catapano^{1,4*} (for the CHECK Group[#])

¹Epidemiology and Preventive Pharmacology Centre (SEFAP), University of Milano, Milano, Italy

²Italian Society of General Medicine (SIMG), Firenze, Italy

³Kingston University, Kingston upon Thames, UK

⁴IRCCS Multimedica, Sesto S. Giovanni, Milano, Italy

Email: alberico.catapano@unimi.it

Received 5 August 2012; revised 15 September 2012; accepted 8 December 2012

ABSTRACT

Objective: To evaluate the distribution of cardiovascular risk factors and the prevalence of cardiovascular disease in a sample of the Italian population. **Methods:** CHECK (*Cholesterol and Health: Education, Control and Knowledge*) is a cross-sectional observational study in a randomised sample of the Italian adult population aged 40 - 79 years, in the setting of general practice. **Results:** 5846 subjects (50.3% male) were included in the analysis. The mean age [\pm SD] of the observed cohort was 57.8 (\pm 10.3) years. One out of five subjects smoked cigarettes and almost 80% didn't engage in regular leisure-time physical activity. The mean blood pressure was 132.0 [\pm 14.7]/81.2 [\pm 7.9] mmHg. The total and LDL-cholesterol levels were respectively 205.3 [\pm 35.9] mg/dL and 124.9 [\pm 29.9] mg/dL. The mean glucose concentration was 98.3 [\pm 28.2] mg/dL. The prevalence rate of hypertension, hypercholesterolemia, and type 2 diabetes were respectively 51.8%, 55.6%, and 13.0%. 8.9% of the observed subjects had a history of cardiovascular events, while in the primary prevention group the 10-year-risk of coronary heart disease (Framingham algorithm) was 10.1% [\pm 8.3%] and of cardiovascular disease (CUORE algorithm) was 5.2% [\pm 5.9%]. **Conclusion:** The CHECK study provides a detailed description of a randomised sample of the Italian population, contributing to evaluate the prevalence of cardiovascular risk factors and the main cardiovascular disease in Italy and to provide a baseline to set priorities and objectives for future intervention of health policy.

Keywords: Italian Population; Epidemiological Study;

*Corresponding author.

[#]As presented in Appendix.

Cardiovascular Risk Factors; Prevalence of Cardiovascular Disease

1. INTRODUCTION

Cardiovascular diseases (CVD), a group of disorders of the heart and blood vessels, including coronary heart disease, cerebrovascular disease, peripheral arterial disease, are the leading cause of morbidity, disability and mortality worldwide, showing a continue increasing trend. In 2008, CVD caused 17 million deaths (47.2% of non-communicable diseases deaths, 29.8% of total deaths in the world) [1]; in particular, 7.6 million deaths were due to ischemic heart disease and 5.7 million to stroke [2].

CVD remains the first cause of death and disability in Italy although a slow and stepwise reduction of incidence has been observed since the mid seventies [3,4].

The subjects who survive acute cardiovascular events are likely to become chronic patients. CVD compromise patients' quality of life and represent a significant economic burden to the national health system. Cardiovascular drugs account for about 26.4% of the Italian Pharmaceutical expenditure [5].

The CHECK (*Cholesterol and Health: Education, Control and Knowledge*) study was designed to provide information on the distribution of the main CVD risk factors in Italy setting the stage for addressing questions relative to the plausibility and feasibility of interventions on the principal risk factors for CVD in an European country.

CHECK is the first randomised Italian epidemiological study performed in primary care. Its main objective was to evaluate the distribution of cardiovascular risk factors and the prevalence of cardiovascular disease in a representative sample of the Italian adult population aged 40 - 79 years. Other aims were 1) to perform a follow-up study to determine the incidence of cardiovascular events

and other main pathologies, 2) to create plasma and DNA banks to design ad-hoc nested case-control studies, 3) to disseminate information about cardiovascular risk factors to increase physicians and patients awareness and contribute to the implementation of evidences supporting health policies and preventive strategies in the population.

In this paper we describe baseline characteristics of enrolled subjects.

2. MATERIAL AND METHODS

The study was conducted in accordance to the Declaration of Helsinki, Guidelines for Good Clinical practice, and the Italian bioethics regulations and laws. The study was approved by the local Ethic Committee and all subjects gave written informed consent to the study (protocol code SEFAP/Pr. 0003).

2.1. Study Design

The Italian Society of General Medicine (SIMG) identified 54 general practitioners (coordinators) that were active at local level and distributed throughout the Italian territory (both rural and urban areas) in proportion to the regional population density. Each coordinator had to contact other general practitioners (GPs) who were operating on the same territory, to reach a group of 14 GPs.

Overall, 764 GPs were invited to participate to the study as investigators. They had to meet all the following pre-requisites:

- age: <52 years;
- practice size: >1000 subjects;
- computerised patient records system;
- access to the web.

The GPs who adhered to the proposal had to register in the project website and to provide some personal information and their patients number. Each investigator was required to enrol 16 subjects aged 40 to 79 years, randomly selected among his patients, following a random number list generated by the coordinating Centre in Milan based on self-reported number of patients. The patient selection procedure was subject to random control by the local coordinators. Subjects who didn't give their consensus or who were not eligible for practical reasons (e.g. subjects with walking disabilities, severe handicap, or suffering from an invaliding disease or a severe mental illness) were excluded from the randomized sample. The subjects' enrolment started in March 2002 and ended in June 2005.

2.2. Data Collection

Subjects' clinical history and clinical information were collected during a standardised visit performed by the

investigating physician.

Information about smoking habit, physical activity, alcohol use and chronic drug treatments were collected directly from the patient during the same examination. Smoking habit was classified as current (patient smoking at least one cigarette per day) or former (at least one year from smoking cessation). Self-reported leisure-time physical activity was classified as present or non-present. The use of alcohol was evaluated by adding the consumption of red and/or white wine, beer and liquors. Information on chronic therapies was also collected.

Weight and height measures, obtained from lightly clothed patients, were expressed in terms of body mass index (BMI, weight in kilos divided by the square value of height, in meters).

The measurement of blood pressure (BP) was performed with the patient in sitting position, after 4 minute of rest, applying the appropriate cuff on the right arm. Systolic and diastolic blood pressure was identified at the beginning of the first and the fifth phase of the Korotkoff sounds, using a mercury sphygmomanometer with the appropriate cuff. Three consecutive readings were recorded and their mean was considered for the analysis. Heart rate was assessed as beats per minute after the last measurement of BP.

The presence of angina pectoris or of a history of myocardial infarction, coronary artery bypass graft or coronary angioplasty, stroke, transient ischemic attacks, *claudicatio* and left ventricular hypertrophy were assessed by retrieving the medical records of the subject and by direct inquiry. Subjects with a history of cardiovascular events (excluding left ventricular hypertrophy) were considered in secondary prevention.

Family history for premature cardiovascular diseases was determined when episodes of stroke and/or myocardial infarction were reported for one or more first-degree relatives, <55 years old for men and <65 years old for women. Family history for hypertension, dislipidemia, and diabetes was also evaluated.

All relevant subject records were entered in a computerized patient chart directly by the investigating physician and then sent to a central server via web.

Blood samples were drawn at the beginning of the enrolment visit. Blood was obtained between 8 to 10 am, from the antecubital vein, in sitting position, after 12 hours of fasting and alcohol abstinence. Blood samples were then collected in EDTA or moniodine-acetate (only for glucose assessment) coated tubes and shipped by courier at 4°C temperature to the central laboratory (Fleming SpA, in Brescia, Italy) within 24 hours, where the biochemical parameters were determined. The biochemical evaluation was performed following the criteria of the World Health Organization Lipid Reference Laboratories.

Upon arrival, the samples were centrifuged to obtain the plasma. Levels of total cholesterol (TC), glucose and triglycerides (TG) were measured by a chromatometric enzymatic method; the plasma levels of apolipoprotein B by a latex enhanced turbidimetric immuno-assay. Plasma HDL cholesterol levels (HDL-C) were measured after the precipitation of the apolipoprotein B containing lipoproteins with dextran-magnesium-chloride. All determinations were performed by an automatic analyzer (AD-VIA 1650; Bayer, Germany). Fibrinogen plasma levels (1.8 - 3.5 g/L) were assessed by a turbidimetric method with Nefelometro BNA 100 (Boehringer, Italia). The low density lipoprotein cholesterol (LDL-C) values were calculated using the Friedewald formula (TC minus HDL-C minus 1/5 TG).

Serum 1 mL aliquots (4 - 5 for each sample) were frozen at -80°C for further biochemical evaluation. White cells were frozen at -20°C for polymorphism search/genetic research.

Criteria used for specific diagnosis were:

- Hypercholesterolemia: plasma levels of TC ≥ 200 mg/dL or LDL-C ≥ 130 mg/dL or pharmacological treatment with statins and/or simvastatin + ezetimibe.
- Hypertriglyceridemia: plasma levels of TG ≥ 170 mg/dL or pharmacological treatment with fibrates and/or omega-3.
- Mixed dyslipidemia: hypercholesterolemia and hypertriglyceridemia, as defined above.
- Hypertension: recorded diagnosis by physician or systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg or currently taking medication to lower high BP (NHANES criteria [6]).
- Type 2 diabetes mellitus: recorded diagnosis by physician or fasting blood glucose levels ≥ 126 mg/dL or currently taking antidiabetic drugs (oral hypoglycaemic medication and/or insulin).
- Overweight: body mass index (BMI) ≥ 25 and <30 kg/m²;
- Obesity: BMI ≥ 30 kg/m²;
- Metabolic Syndrome (MetS): presence of at least 3 of 5 of the listed characteristics [7]: abdominal obesity, given as waist circumference, men > 102 cm, women > 88 cm; triglycerides ≥ 150 mg/dL; HDL cholesterol, men < 40 mg/dL, women < 50 mg/dL; blood pressure $\geq 130/85$ mmHg; fasting glucose ≥ 110 mg/dL. BMI was used as a surrogate of waist circumference, men ≥ 28 kg/m², women ≥ 25 kg/m² (approach validated in a subgroup of about 1000 subjects: assignment to MetS/noMetS consistent in 92% of cases in males and 97% in females).

The coronary heart disease risk (CHD risk % in 10 years) was calculated using the Framingham algorithm [8], as recommended at the time of the study by the Italian regulatory Agency (AIFA) for the prescription of

statin drugs [9]; the global cardiovascular risk (CVD risk % in 10 years) was evaluated using the CUORE algorithm [10], developed from epidemiological data obtained in Italy, as reported by Italian recommendations since 2003 [11]. Based on Framingham or CUORE scores, subjects were stratified in four risk classes ($<5\%$ low-risk; 5% - 10% mild-risk; 10% - 20% moderate-risk; $\geq 20\%$ high risk).

2.3. Statistical Analysis

Normally distributed variables are presented as mean values [\pm standard deviation, SD] and not normally distribute variables as median [interquartile range, IQR], while qualitative variables are presented as frequencies. Comparisons between continuous variables across sex groups were performed by using the t-test for independent sample. Comparisons between proportions across sex groups for categorical (and qualitative) variables were performed by using non-parametric tests. All reported p-values are based on two-sided tests and compared to a significance level of 5%.

All statistical analyses were performed using the Windows 16.0 version of SPSS (SPSS, Inc., Chicago, Illinois).

3. RESULTS

432 GPs participated to the CHECK study (mean age 47.8 years, 80.1% male; 56.5% participation rate). Each of them enrolled up to 16 subjects, following the randomised sampling procedure. Overall, 6890 subjects were enrolled; 1044 (15.1%) of them did not attend the medical visit and were excluded from the study sample; the blood samples of 131 subjects (1.9%) were not processable, although their anamnestic data were included in the analysis.

5846 subjects were included in the final analysis (**Figure 1**). Men were 49.7% of the cohort. The mean age was 57.8 years (58.2 years for men and 57.4 for women). Comparison between the Check demographics and the latest available census data [12] showed small difference: women were slightly under-represented in the CHECK sample (50.3% vs. 52.6% respectively); the 50 - 59 and 60 - 69 age groups, conversely, were slightly over-represented (30.5% vs. 27.0% and 28.0% vs. 24.6%, respectively).

The main outcomes of the study are shown in **Tables 1-4**. The average level of education is quite low: 33.0% of subjects achieved only primary education, but this percentage was higher in women (36.7% vs. 29.2%). 32.9% reported to be retired, with a high proportion of men (65.8%); 23.3% were housewives (45.8% of the female sample). Smoke habit and alcohol consumption were more prevalent in men (24.3% vs. 18.6% and 62.4% vs. 28.4%, respectively), whereas physical inac-




Figure 1. Flow chart of the study.

tivity was more present in women (84.1% vs. 75.0%) (**Table 1**).

Mean BMI (\pm SD) was 26.5 ± 4.3 kg/m², putting the sample in the overweight range; this was observed in both genders. Mean SBP/DPB values were $(132.0 \pm 14.7)/(81.2 \pm 7.9)$ mm Hg, slightly higher than cut off for pre-hypertension. Mean total cholesterol was 205.3 ± 35.9 mg/dL, while LDL-cholesterol was 124.9 ± 29.9 mg/dL, the former just higher and the latter slightly lower than desirable levels, due to HDL-cholesterol values (54.8 ± 12.2 mg/dL) (**Table 2**).

As shown in **Table 3**, 51.8% of subjects were hypertensive, 13.0% were diabetic, and 55.6%/20.8% were hypercholesterolemic/hypertriglyceridemic. 8.6% had a history of cardiovascular events and thus could be defined as in secondary CV prevention. The 65.0% of the remaining subjects had a global CV risk in 10 years (calculated with CUORE algorithm) lower than 5%, with a remarkable difference between genders (mean values: $7.8\% \pm 7.1\%$ in men vs. $2.8\% \pm 3.1\%$ in women) (**Table 4**).

4. DISCUSSION

The main objective of the CHECK study was to evaluate the cross-sectional prevalence of CVD and cardiovascular risk factors in a cohort of randomly selected Italian subjects, aged 40 to 79 years.

The CHECK sample proved to be representative of the Italian population in the same age range. The differences observed by comparing the Check demographics to the latest available census data [12] are small, and of limited relevance. This was probably due to a larger participation

to the study of subjects in a non-working age or condition.

The CHECK study provided a detailed and in depth description of the prevalence of cardiovascular risk factors and the main cardiovascular pathologies in the Italian population. In order to put our findings into a wider context, we compare them with other national surveys, while maintaining a worldwide perspective.

Smoking is estimated to cause nearly 10% of cardiovascular disease (5.4 millions of deaths) [13]. Currently, there are about 1 billion smokers worldwide [14]. The proportion of smoking subjects in the CHECK sample was 21.4% (men 24.3% and women 18.6%). These figures were slightly lower than the official census data (24.5% in 2003, 22.6% in 2004) [15]; the Check cohort excluded the 25 - 34 age group, the one with the highest prevalence of smokers (31.4%), especially among men. The reduced prevalence of smokers in the CHECK cohort, as compared to previous epidemiological data [16], could also reflect the declining smoking habits in the Italian population, as a result of educational programs and smoking restrictions enforced in public buildings.

Physical inactivity is one of the leading risk factors for mortality and is estimated to cause about 30% of ischaemic heart disease burden [13]. Globally, around 31% of adults are insufficiently active (men 28% and women 34%) [17]. Concerning leisure-time physical activity, the self-reported information obtained from the CHECK cohort were less favourable than the data derived from other studies. The prevalence of physical inactivity was 75% in men and 84% in women, vs. 34% in men and 46% in women observed, as an example, in the Atlante study [18].

Overweight and obesity lead to adverse metabolic effects on blood pressure, cholesterol, triglycerides and insulin resistance [13]; all over the world, 2.8 million people die each year as a result of being overweight [13]. A total of more than half a billion adults worldwide are obese [19]. The mean BMI of the CHECK cohort was 26.5 kg/m², well within the overweight range. 17.4% of the cohort subjects were obese, with a higher prevalence in women than in men (18.8% vs. 16.0%, respectively). In the PASSI study, a national survey (self-reported information) conducted on younger people aged 18 - 69 years [20], 32% of Italians are overweight, while one in ten is obese [21].

Raised blood pressure is the leading risk factor for cardiovascular disease mortality, causing more than 7 million deaths every year worldwide. Globally, prevalence of hypertension in adults is around 40% [13]. In our study, the mean blood pressure value was $132.0/81.2$ mmHg. Hypertension was present in more than half of the sample, with a higher prevalence in men (54.1% M vs. 49.5% W). The CHECK mean SBP values were comparable to those obtained in other Italian observational

Table 1. Sociodemographic and lifestyle characteristics in total and sex-stratified sample.

	Total sample	Men	Women
Subjects, n (%)	5846	2903 (49.7)	2943 (50.3)
Age, mean \pm SD ($^{\circ}$)	57.8 \pm 10.3	58.2 \pm 10.1	57.4 \pm 10.5
Age distribution, N (%)§			
40 - 49 years	1517 (26.0)	689 (23.7)	828 (28.1)
50 - 59 years	1784 (30.5)	912 (31.4)	872 (39.6)
60 - 69 years	1638 (28.0)	844 (29.1)	794 (27.0)
70 - 79 years	907 (15.5)	458 (15.8)	449 (15.3)
Occupational status, N (%)§			
Employed	2109 (36.5)	1360 (47.4)	749 (25.8)
Housewife	1347 (23.3)	14 (0.5)	1333 (45.8)
Retiree	1902 (32.9)	1252 (43.7)	650 (22.3)
Unemployed	51 (0.9)	33 (1.2)	18 (0.6)
Other	367 (6.4)	207 (7.2)	160 (5.5)
Educational level (highest degree), N (%)§			
None	98 (1.7)	37 (1.3)	61 (2.1)
Elementary	1905 (33.0)	836 (29.2)	1069 (36.7)
Junior high	1840 (31.9)	916 (32.0)	924 (31.8)
High school	1488 (25.8)	808 (28.2)	680 (23.4)
University	445 (7.7)	269 (9.4)	176 (6.0)
Life habits, N (%)§			
Smokers	1253 (21.4)	706 (24.3)	547 (18.6)
Regular exercise	1181 (20.4)	717 (25.0)	464 (15.9)
Alcohol users	2613 (45.2)	1788 (62.4)	825 (28.4)

*Men vs. women (t-test) $p < 0.003$; § Men vs. women (non-parametric tests) $p < 0.05$.

Table 2. Anthropometric, vital and biochemical parameters in total and sex-stratified sample, mean \pm SD.

		Total sample	Men	Women *
Height (m)	N = 5843	1.65 \pm 0.09	1.71 \pm 0.07	1.60 \pm 0.07
Weight (kg)	N = 5835	72.5 \pm 13.4	78.5 \pm 11.7	66.6 \pm 12.4
BMI (Kg/m 2)	N = 5835	26.5 \pm 4.3	26.9 \pm 3.5	26.2 \pm 4.9
SBP (mmHg)	N = 5844	132.0 \pm 14.7	133.0 \pm 13.8	130.9 \pm 15.5
DBP (mmHg)	N = 5844	81.2 \pm 7.9	81.9 \pm 7.8	80.6 \pm 8.0
Heart rate (bpm)	N = 5773	73.3 \pm 8.5	72.6 \pm 8.5	74.0 \pm 8.5
TC (mg/dL)	N = 5710	205.3 \pm 35.9	202.5 \pm 35.7	208.0 \pm 35.9
HDL-C (mg/dL)	N = 5710	54.8 \pm 12.2	50.7 \pm 10.4	58.8 \pm 12.4
TG (mg/dL)	N = 5710	132.8 \pm 102.1	149.9 \pm 120.6	115.9 \pm 76.1
median [IQR]		109 [78 - 157]	119 [86 - 177]	98 [72 - 140]
LDL-C (mg/dL) §	N = 5614	124.9 \pm 29.9	123.3 \pm 29.3	126.5 \pm 30.3
ApoB (mg/dL)	N = 5710	111.4 \pm 25.2	112.5 \pm 25.3	110.4 \pm 25.1
Non-HDL-C (mg/dL) $^{\#}$	N = 5710	150.5 \pm 33.8	151.8 \pm 33.6	149.2 \pm 34.0
Glucose (mg/dL)	N = 5547	98.3 \pm 28.2	101.7 \pm 29.6	94.9 \pm 26.3
median [IQR]		92 [84 - 102]	95 [87 - 106]	89 [83 - 98]
Fibrinogen (g/L)	N = 5710	3.41 \pm 0.69	3.34 \pm 0.70	3.47 \pm 0.68

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglycerides; apoB: apolipoprotein B; * Men vs women (t-test) $p < 0.01$ for all comparisons; § Obtained by the Friedewald formula; $^{\#}$ (TC) - (HDL-C).

Table 3. Prevalence of cardiovascular disease and related comorbidities in total and sex-stratified sample, N (%).

		Total sample	Men	Women	p*
Comorbidities					
Hypertension ^o	N = 5774	2990 (51.8)	1549 (54.2)	1441 (49.5)	<0.001
Hypercholesterolemia ^o	N = 5707	3172 (55.6)	1514 (53.5)	1661 (57.9)	<0.001
Hypertriglyceridemia ^o	N = 5707	1191 (20.8)	780 (27.8)	411 (14.5)	<0.001
Mixed dyslipidemia ^o	N = 5707	935 (14.8)	598 (21.3)	337 (11.9)	<0.001
DM2 ^o	N = 5568	723 (13.0)	432 (15.6)	291 (10.4)	<0.001
Obesity ^o	N = 5853	1011 (17.3)	463 (16.0)	552 (18.8)	<0.01
Metabolic syndrome ^o	N = 5660	1306 (23.1)	629 (22.3)	677 (23.8)	NS
Cardiovascular events					
Stable angina	N = 5846	113 (1.9)	68 (2.3)	45 (1.5)	<0.05
Unstable angina	N = 5846	74 (1.3)	48 (1.7)	26 (0.9)	<0.05
Myocardial infarction	N = 5846	180 (3.1)	154 (5.3)	26 (0.9)	<0.001
CABG	N = 5846	46 (0.8)	39 (1.3)	7 (0.2)	<0.001
PTCA	N = 5846	76 (1.3)	65 (2.2)	11 (0.4)	<0.001
Transient ischemic attack	N = 5846	118 (2.0)	71 (2.4)	47 (1.6)	<0.05
Ischemic stroke	N = 5846	41 (0.7)	25 (0.9)	16 (0.5)	NS
Claudicatio	N = 5846	82 (1.4)	73 (2.5)	9 (0.3)	<0.001
Secondary prevention [^]	N = 5846	501 (8.6)	354 (12.2)	147 (5.0)	<0.001
LVH	N = 5846	526 (9.0)	288 (9.9)	238 (8.1)	<0.05
Family history					
Coronary heart disease	N = 5846	681 (11.6)	323 (11.1)	358 (12.2)	NS
Cerebrovascular disease	N = 5846	454 (7.8)	205 (7.1)	249 (8.5)	NS
Dyslipidemia	N = 5846	1579 (27.0)	763 (26.3)	816 (27.7)	<0.001
Hypertension	N = 5846	2897 (49.6)	1346 (46.4)	1551 (52.7)	<0.001
DM2	N = 5846	1542 (26.4)	740 (25.5)	802 (27.3)	NS

DM2: type 2 diabetes mellitus; CABG: coronary artery bypass graft surgery; PTCA: percutaneous transluminal coronary angioplasty; LVH: left ventricular hypertrophy; NS: not significant; ^oCriteria used for specific diagnosis are described in Methods paragraph; [^]Criteria for definition are described in Methods paragraph; *Men vs. women (non-parametric tests).

Table 4. CHD-risk classes and CVD-risk classes in total and sex stratified sample.

	Framingham			CUORE		
	Total sample	Men	Women	Total sample	Men	Women
Risk %, mean \pm SD ^o	10.1 \pm 8.3	13.5 \pm 8.9	7.0 \pm 6.3	5.2 \pm 5.9	7.8 \pm 7.1	2.8 \pm 3.1
Risk classes, n (%)[§]						
<5.0%	1415 (30.8)	299 (13.6)	1116 (46.6)	2736 (65.0)	916 (45.4)	1820 (83.2)
5.0% - 9.9%	1420 (30.9)	627 (28.4)	793 (33.1)	858 (20.4)	566 (28.0)	292 (13.4)
10.0% - 19.9%	1257 (27.3)	884 (40.1)	373 (15.6)	470 (11.2)	403 (20.0)	67 (3.1)
\geq 20.0%	505 (11.0)	394 (17.9)	111 (4.6)	142 (3.4)	126 (6.6)	8 (0.4)

^oValues calculated within the limits of each algorithm; *Men vs. women (t-test) p < 0.001; [§]Men vs. women (non-parametric tests) p < 0.001.

studies, while the DBP values resulted slightly lower (82 - 86 mmHg) [18]. Compared to the population sample observed in the Atlante study, the CHECK cohort showed a higher overall incidence of hypertensive subjects (52% M vs. 45% W), possibly due to a higher prevalence of older subjects in the CHECK sample.

Raised total cholesterol is a major cause of disease burden as a risk factor for ischaemic heart disease and stroke. Overall, it is estimated to cause 2.6 million deaths (4.5% of total). The global prevalence of hypercholesterolemia among adults is about 39% [13]. The mean plasma total cholesterol levels in the CHECK cohort were 205.3 mg/dL. The prevalence of hypercholesterolemia was 55.6%. Hypertriglyceridemia and mixed dyslipidemia were identified in 20.8% and 14.8% of the enrolled subjects, respectively. Lipid data observed in the CHECK and in the Atlante study showed relevant similarities: in both cohorts, women showed a higher level of TC, LDL-C, and HDL-C than the same level reported for men, but lower TG values. TC mean values observed in the CUORE population [22], on the other hand, were significantly higher than those found in CHECK (CUORE 225.4 mg/dL M and 229.0 mg/dL W vs. CHECK 202.5 mg/dL M and 208.0 mg/dL W). This difference is consistent with the trend of progressive reduction of blood TC levels observed over the last decades in Italy.

Impaired glucose tolerance and impaired fasting glycaemia are risk categories for future development of diabetes and cardiovascular disease [23]. A 2004 survey showed that more than 3 million people died from consequences of high blood sugar [24]. The global prevalence of diabetes is estimated to be 10% [13]. In the CHECK cohort, the mean level of fasting glucose was 98.3 mg/dL (101.7 M vs. 94.9 W). Based on GPs diagnosis and/or presence of anti-diabetes therapies and/or plasma glucose levels ≥ 126 mg/dL, type II diabetes prevalence was 13.0%. This prevalence was higher than that observed in the Health Search GP's database of Italian general practice [25] for similar age (10% - 11%; unpublished observation). This difference can be partially explained by different diagnostic criteria (based on at least two assessments in clinical practice compared to the single time determination in the CHECK study protocol), or by the identification of previously unknown cases in the CHECK sample, due to the generalised screening. In the Atlante cohort, the mean fasting glucose levels was lower (93 mg/dL M vs. 87 mg/dL W), leading to a lower prevalence of type II diabetes (Atlante 9% M and 6% W vs. CHECK 15.6% M and 10.4% W). This difference could be partially explained by the different timeframe of the two studies (Atlante from 1998 vs. CHECK from 2001): over the last years, a generalised increase in the prevalence of type II diabetes in Western populations has been observed. Moreover, in the

Atlante study the blood glucose level was estimated from a sample of capillary blood, where glucose concentrations are on average significantly lower than in plasma.

Cardiovascular disease is the number one cause of death globally. In Italy, an estimated almost 240,000 people died from CVDs in 2008, representing 41% of all total deaths [26]. A clinical history of previous cardiovascular events was observed in 8.6% of the individuals included in the CHECK sample. The prevalence of such diagnosis was twice as high in men than in women. The prevalence of a clinical history of myocardial infarction was higher in the CHECK than in the Atlante study, especially in men (CHECK 5.3% M and 0.9% W vs. Atlante 1.5% M and 0.4% W). The difference could be explained by the different methodological approach (information collected in a GP interview vs. hospital validation) and age differences.

The risk of future fatal and non-fatal cardiovascular events was assessed using two different algorithms, based on the outcomes of the Framingham and the Cuore cohorts. The mean coronary risk at 10 years, calculated with the Framingham algorithm, was 10.1%, while the cardiovascular risk calculated with the CUORE algorithm showed an average value of 5.2%. This difference was expected, since the Framingham algorithm is known to over-estimate the coronary risk of the Italian population [27]. Compared to the CUORE population data [28], the mean cardiovascular risk for the CHECK cohort was slightly lower (CUORE 7.8% M and 2.8% W vs. CHECK 8.7% M and 3.3% W).

The innovative design of the CHECK study responded to the emerging need of determining the prevalence of cardiovascular risk factors directly from primary care, following a rigorous and unbiased research methodology. The randomisation of the sample, the web-based data collection of primary data, the territorial quality control operated by local coordinators, and the centralised laboratory procedures increase the external validity of the study, conferring a general significance to the epidemiological outcomes.

A follow-up of the cardiovascular events (fatal and nonfatal) occurred to all enrolled subjects is currently ongoing. It will provide the opportunity to evaluate the underlying prevalence of factors predisposing the onset of cardiovascular disease. Moreover, frozen samples provide the possibility of further biochemical evaluations, as the characterization of specific population subgroups through polymorphism search/genetic research.

The assessment of the gap between risk factor levels and recommended targets will provide evidence to aid clinical decision making about tailored non pharmacological and pharmacological interventions and to achieve optimal resources allocation.

The CHECK study has some methodological limita-

tions, previously described. Importantly, the prevalence of cardiovascular events could have been underestimated, as the participating general practitioners reported those events at best of their knowledge, simply transcribing the diagnose related groups (DRG) codification of the events as reported by the hospital discharge letter, without any form of control on the appropriateness of the diagnoses. In addition, the peculiar design of the study, with progressive steps of GPs involvement, determined a participation rate lower than expected. The fact that local investigators did not participate in the enrolment meetings with the coordinating Centre, but were trained by their coordinators, may have weakened their motivation. However, no significant differences have been found between actively participating GPs and those who did not complete the preliminary steps.

5. CONCLUSIONS

The CHECK study confirmed the significant burden caused by the cardiovascular disease to the health care system and to society. In the randomised cohort observed, 1 out of 2 subjects was suffering from high blood pressure or high cholesterol, 1 out of 5 was obese and 1 out of 10 was a type 2 diabetic. The elevated prevalence of lifestyle risk factors observed in the Italian population raises the issue of moral hazard: the limited willingness of subjects covered by the National Healthcare System to take action and modify behavioural risks, in favour of deferring the issue to pharmacological prevention or treatment of the cardiovascular events at a later stage. While this normative issue is well known in economics of public health, the CHECK findings on the prevalence and co-occurrence of key behavioural and clinical risk factors is an emerging concern and it demands further research. Despite the fact that most subjects included in the study had been followed-up by general practitioners for years, the vast majority of them still showed the presence of one or more risk factors.

The high proportion of subjects with multiple risk factors in combination with the elevated prevalence of cardiovascular disease projects a shadow on the effectiveness of current cardiovascular prevention policies in primary care. The epidemiological outcomes of this study could be used as a baseline to set priorities and objectives for future intervention, as well as a benchmark, against which the effectiveness of the implementation of future prevention policies in primary care should be measured. The further development of the CHECK study is aimed to facilitate the recognition and to improve the management of cardiovascular diseases in the Italian general practice.

6. ACKNOWLEDGEMENTS

The CHECK study was supported in part by an unconditioned educa-

tional grant from AstraZeneca SpA. Thanks to Maria Grazia Lanfranco and Elena Loggia for their assistance in completing our survey.

REFERENCES

- [1] Alwan, A., Maclean, D.R., Riley L.M., *et al.* (2010) Monitoring and surveillance of chronic non-communicable diseases: Progress and capacity in high-burden countries. *Lancet*, **376**, 1861-1868. [doi:10.1016/S0140-6736\(10\)61853-3](https://doi.org/10.1016/S0140-6736(10)61853-3)
- [2] Fuster, V. and Kelly, B.B. (2010) Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries. Institute of Medicine. National Academies Press, Washington.
- [3] ERA (2009) *Epidemiologia e Ricerca Applicata*. http://www.atlantesanitario.it/index.php?option=com_content&view=article&id=82&Itemid=93
- [4] ISTAT (2012) GeoDEMO. <http://demo.istat.it/unitav/index.html?lingua=ita>
- [5] AIFA (2012) Rapporti OsMed—L'uso dei farmaci in Italia. <http://www.agenziafarmaco.gov.it/it/content/rapporti-osmed-luso-dei-farmaci-italia>
- [6] CDC (2011) National Health and Nutrition Examination Survey. <http://www.cdc.gov/nchs/nhanes.htm>
- [7] Adult Treatment Panel III (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *Journal of the American Medical Association*, **285**, 2486-2497. [doi:10.1001/jama.285.19.2486](https://doi.org/10.1001/jama.285.19.2486)
- [8] Anderson, K.M., Wilson, P.W., Odell, P.M. and Kannel, W.B. (1991) An updated coronary risk profile. A statement for health professionals. *Circulation*, **83**, 356-362. [doi:10.1161/01.CIR.83.1.356](https://doi.org/10.1161/01.CIR.83.1.356)
- [9] AIFA (2012) Le nuove note CUF. BIF 5-6/2000. <http://www.agenziafarmaco.gov.it/it/content/bif-5-62000>
- [10] Palmieri, L., Panico, S., Vanuzzo, D., *et al.* (2004) Evaluation of the global cardiovascular absolute risk: The Progetto CUORE individual score. *Ann Ist Super Sanita*, **40**, 393-399.
- [11] AIFA (2012) Le note. BIF 2/2004. <http://www.agenziafarmaco.gov.it/it/content/bif-22004>
- [12] ISTAT (2012) 14 censimento generale della popolazione e delle abitazioni. <http://dawinci.istat.it/MD/>
- [13] WHO (2009) Global health risks mortality and burden of disease attributable to selected major risks. World Health Organization, Geneva.
- [14] WHO (2012) Tobacco. <http://www.who.int/mediacentre/factsheets/fs339/en/index.html>
- [15] ISTAT (2012) Condizioni di salute e ricorso ai servizi sanitari: I fumatori in Italia. http://www3.istat.it/salastampa/comunicati/non_calendari/20060110_00/

- [16] Zuccaro, P., Pacifici, R., Giampaoli, S., *et al.* (2001) Fumo: Il contesto epidemiologico nazionale. *Ital Heart Journal*, **2**, 13-18.
- [17] WHO (2012) Physical inactivity: A global public health problem. http://www.who.int/dietphysicalactivity/factsheet_inactivity/en/
- [18] OEC (2004) Atlante italiano delle malattie cardiovascolari—Second edition. *Ital Heart Journal*, **5**, 1S-101S.
- [19] Finucane, M.M., Stevens, G.A., Cowan, M.J., *et al.* (2011) National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet*, **377**, 557-567. doi:10.1016/S0140-6736(10)62037-5
- [20] Baldissera, S., Campostrini, S., Binkin, N., *et al.* (2011) Features and initial assessment of the Italian Behavioral Risk Factor Surveillance System (PASSI), 2007-2008. *Preventing Chronic Disease*, **8**, A24.
- [21] Trinito, M., Bertozzi, N., Bietta, C., *et al.*, (2006) Analisi di alcuni fattori di rischio cardiovascolari nella popolazione delle ASL partecipanti allo studio PASSI. *Notiziario dell'Istituto Superiore di Sanità*, **19**, iii-iv.
- [22] ISS (2012) Il Progetto CUORE: Assetto lipidico. <http://www.cuore.iss.it/fattori/colesterolemia.asp>
- [23] Levitan, E.B., Song, Y., Ford, E.S. and Liu, S. (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. *Archives of Internal Medicine*, **164**, 2147-2155. doi:10.1001/archinte.164.19.2147
- [24] WHO (2012) Diabetes. <http://www.who.int/mediacentre/factsheets/fs312/en/>
- [25] Filippi, A., Vanuzzo, D. Bignamini, A.A., Sessa, E. Brignoli, O. and Mazzaglia, G. (2005) Computerized general practice databases provide quick and cost-effective information on the prevalence of angina pectoris. *Ital Heart Journal*, **6**, 49-51.
- [26] WHO (2011) Noncommunicable diseases country profiles. World Health Organization, Geneva.
- [27] Menotti, A., Puddu, P.E. and Lanti, M. (2000) Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. *European Heart Journal*, **21**, 365-370. doi:10.1053/euhj.1999.1864
- [28] ISS (2012) Il Progetto CUORE: Rischio cardiovascolare globale assoluto. <http://www.cuore.iss.it/fattori/RischioGlobaleAssoluto.asp>

Appendix

Participating Investigators in the CHECK Study Group (Bold Type for Coordinators)

Aalders Maria Anna	Buzzatti Agostino	Durando Andrea	La Torre Angelo
Abbate Giuseppe	Caccamo Orazio Antonio	Ercolino Luigi	Lacava Cosimo
Agati Riccardo	Cadamosti Danilo	Fabbri Stelania	Lalli Pasqualino
Alano Raffaele	Cagliesi Francesco	Fabrizio Nicola	Lamera Giorgio
Alba Mauro	Caleffa Manuela	Falchi Raffaello	Lanza Gerardo
Alemagna Silvia	Cammissa Nicolò	Fariello Ciro	Lardo Gerardo
Alunni Massimo	Campo Francesco	Fascendini Emilvio	Laringe Matteo
Alvaro Antonio	Campobello Margherita	Fasulo Serenella	Lattanzio Giuseppe
Amato Fabio	Caputo Stanislao	Federici Laura	Le Foche Luca
Ammendola Erminia	Caraccio Nicola	Ferioli Paolo	Leo Rosanna
Amodeo Vincenzo	Cardi Silvio	Ferrari Vincenzo	Leuzzi Giacomo
Amoretti Giovanni	Cardinale Fulvio	Fidelbo Melchiorre	Lipari Antonino
Andrani Alberto	Caregnato Massimo	Filetti Giuseppe	Lipari Francesco
Antiga Ivo	Cariola Gianni	Filippini Giovanni	Lippa Luciano
Appolonia Giorgio	Carlino Saverio	Fogher Michele	Lo Conte Maurizio
Aramini Enrico	Carminati Luisa Angela	Franchini Carlo Andrea	Lo Giudice Domenico
Arisi Marco Emilio	Carnelli Feliciano	Frascati Angelo	Lonati Rossella
Artebani Adriano	Carnesalli Franco	Frignani Patrizia	Lorenzina Enrico
Atzei Massimiliano	Caruso Ciro	Fronteddu Pier Francesco	Magi Lorenzo
Azzolini Micheline	Casale Ezio	Gadaleta Caldarola Gennaro	Magliozzo Francesco
Bachetti Francesco	Casini Marcella	Galandini Giovanna	Mallamo Luciano
Bagagli Franco	Cassanelli Marco	Gallicchio Nicola	Mantovani Licia
Baldicchi Lorella	Castiello Maria Luisa	Gallina Franco	Marcenaro Alessandro
Banzi Roberta	Castriotta Antonio	Gallo Silvano	Marchetti Anna Rosa
Barba Ettore Maria	Catalano Domenico	Gambino Fortunato	Mariano Carlo
Barbato Pasquale Claudio	Cataldi Maria Elvira	Gambuzza Guglielmo	Marino Antonino
Barral Gino	Ceccarini Agostino	Garaffa Elio	Mariuz Manuela
Battaglia Alessandro	Celebrano Mario	Garagiola Alberto	Maroni Achille
Battigelli Dorianò	Celora Amedeo	Garofalo Remigio	Martori Ampelio
Baudi Marina	Cerracchio Alessandro	Garrone Alfonsino	Masoch Gigliola
Bellumori Giovanni	Cesaro Andrea	Gatta Luigi	Mattioli Carlo
Beltrami Giuseppe	Cesaro Federico	Gennari Massimo	Mattioli Mauro
Benincasa Anna Maria	Chiriatti Alberto	Gerace Antonio	Maurici Vincenzo
Berardi Mario	Cipriani Rosa	Geremia Maria Alessandra	Mauro Nicola
Berlengiero Claudio	Collura Giuseppe	Germini Fabrizio	Mazzardi Lidia
Bernardelli Stefano	Colombo Valter	Giacci Luciano	Mazzi Wainer
Bernardi Giuseppe	Coluccia Salvatore	Giannini Olivia	Mazzocchetti Alvaro
Bertelle Evandro	Conte Sergio	Giordano Stefano	Mazzoleni Francesco
Bettini Gianluca	Corda Andrea	Giovannelli Umberto	Mazzorana Michela
Bevacqua Giuseppe	Costa Roberto	Giuffrè Giuseppe	Medagliani Giorgio
Bevilacqua Stefano	Cottani Antonio	Giunti Giuliana	Medea Gerardo
Bianconi Giuseppe	Crivellenti Giuseppe	Glaviano Bruno	Merlino Giovanni
Biggioggero Giovanni	D'Ambrosio Gaetano	Gorletta Giovanni	Merone Laura
Bini Vincenzo	D'Angelo Massimo	Grand Paola	Metrucci Antonio
Bocchino Giancarlo	Dalla Rosa Rosanna	Grassini Giovanni	Mezzano Silvio
Boccone Nicolfranco	Damico Giansanto	Grasso Anna Maria	Micchi Alessio
Boito Giancarlo	De Andreis Bessone Pier Luigi	Grasso Giuseppe	Micheli Pietro Severo
Bollo Alberto Maria	De Benedictis Antonio	Grasso Maria Filomena	Milazzo Vito
Boncompagni Salvatore	De Conto Umberto	Greco Agostino	Minafra Francesco
Bond Giuseppe	De Mola Cosimo	Grifagni Marcello	Minetti Luca
Bonesi Maria Grazia	De Rosa Antonio	Grilli Piero	Mirandola Cipriano
Bono Gianfranco	De Tommasi Roberto	Grimaldi Emanuela	Monari Gianluigi
Boscaro Federica	Del Nero Barbara	Grimaldi Nicola	Mongiello Claudio
Bossi Paolo	Della Briotta Ivana	Grosso Marco	Montano Giovanni
Bozza Giulio	Dell'Orco Mario Domenico	Guarnera Lucia	Montera Carmine
Bracone Enrico	Dell'Orco Mario Lucio	Guerra Antonio	Moretti Marino
Brandodoro Lucio	Di Candia Giuseppe	Guillaro Bruno	Morgana Ignazio
Brascesco Pierclaudio	Di Carlo Vittorio	Gussoni Barbara Rita	Morganti Mauro
Breviario Adele	Di Febo Enrico	Ianiro Gabriella	Morile Annunziata
Brizzi Antonio	Di Feo Antonio	Ilardi Salvatore	Moro Roberto
Brugnetta Maurizio	Di Fraia Giovanni	Imbalzano Pasquale	Mostacciolo Francesco
Bruno Giuseppe	Di Fulvio Aristide	Inguscio Cherubino	Mourglià Danilo
Buemi Giuseppe	Di Nardo Dionisio	Invernizzi Giovanni	Murari Tiziana
Bufano Carmine	Dolmetta Franco	Iocca Tommaso	Muratore Alessandro
Bugli Tiziano	Donzelli Luigi	Kos Egidia	Murgia Rosalba
Burigo Daniela	Dughiero Fausto	La Mattina Rosolino	Naccari Massimo

Napoli Luigi
 Nardacci Giuseppe
 Nebiacolombo Cristina
Negri Fabrizio
 Nicolini Gianfranco
Nigro Antonio
Noia Emanuela
Nuti Claudio Pietro
 Olivani Enrico
 Orlando Celestina
 Padovan Letizia
 Padula Maria Stella
Pagan Maurizio
 Pannacci Valerio
 Pantalone Vincenzo
 Paolini Italo
 Papandrea Giampaolo
 Papini Giovanni
 Papulino Francesco
 Paradisi Enza
 Parisi Carmela
 Parretti Damiano
 Pasculli Domenico
 Pasinelli Pietro Carlo
Pasqualetto Salvatore
 Passamonti Marco
 Passaro Vincenzo
 Pederzani Fabio
 Pedrazzoli Giuliano
 Pelizzari Pier Carlo
 Pernici Pierrenato
 Pesaresi Carlo
Pesce Gian Luigi
 Petrucci Marco
 Petrucci Mauro
 Petrucci Carmela
Petti Stefano
Piccinocchi Gaetano
 Picciotto Rinaldo
 Piccolo Francesco
 Pierobon Ivo
 Pilone Rita
 Piva Roberto
Pizzillo Carlo
 Plebani Franco
 Polistina Stefano
 Pontari Antonino
 Poppi Maria Cristina
 Portanti Carla
 Prencipe Giovanni
 Prestifilippo Alessandro
 Procopio Antonio
Profeta Gaetano
 Proietti Carlo
 Quattrocchi Pietro
 Raciti Teodoro
 Ragazzoni Anna
 Rattini Emanuela
 Reale Emanuela
Redaelli Dario
 Reggiani Claudio
 Ricotta Giuseppe
 Rigamonti Rodolfo
 Righini Velella
 Rinaldi Vanna
 Rista Pierangela
 Romano Salvatore
 Romei Federico
 Rossi Alberto
Rossi Angelo
 Rossi Francesco
 Rossi Gianluca
 Rosso Lucia
 Rovazzani Massimo
 Rovelli Monica
 Rovescala Pietroclaudio
 Rubicini Giuseppe
Rubini Stefano
 Russo Carolina
 Russo Vincenzo
 Sala Massimo
 Salurso Daniele
 Salvaderi Maria Dionice
 Salvato Alberto
Salvetti Andrea
Salvio Giuliano
 Samani Fabio
Sammarco Renato
 Santoemma Luigi
 Santoro Michele
 Sassarini Graziano
 Savino Andrea
 Scaglione Matteo
 Scarano Libero
 Schiavone Ciro
 Scola Vincenzo
 Scorpiniti Anna
 Scotto D'Antuono Antonio
 Scovotto Maria Antonietta
 Scuri Maurizio Giovanni
 Scuteri Antonio
Sebastianelli Giuliano
 Sebben Maurizio
Sforza Pasqualino
 Sfragara Ignazio
 Sicari Giuseppe
 Simonini Giorgio
 Soldani Miriam
 Soverina Patrizio
 Spagnolo Beatrice
 Sperandio Massimo
 Spezzano Alfredo
 Steri Lia
 Storni Paolo
 Strada Sonia
 Stramenga Carlo
 Tagliabue Paola Fausta
 Tarabini Legnoaura
Tarallo Nicola
 Tei Alessandro
 Tei Gian Paolo
 Testi Sergio
 Testolin Ennio
 Tibo Angela
 Titone Nicolò
 Tomasello Antonino
 Tondi Lidia
 Torti Giorgio Tommaso
 Toscano Emanuele
 Tota Maria Fiorenza
 Tozzoli Alfonso
 Travaglini Rita
 Trois Paolo
 Trotta Gaetano
 Tuia Bruno
Turbil Enrico
 Ughetti Claudio
 Urru Cesare
 Valdevit Maria
 Valente Fabio
 Valenti Marco
 Valle Lucia
 Valletta Domenico
 Valore Salvatore
 Varriale Antonio
 Varrica Gaetano
 Ventriglia Giuseppe
Venturelli Antonio
 Vesco Giuseppe
 Vezzosi Angelo
 Viola Dario
 Viscusi Bruno
 Vita Salvatore
 Vitali Franco
 Vittozzi Dante Sergio
 Vivona Giacomo
 Volpe Augusto
 Volponi Damiano Antonio
 Voza Italo
 Zadra Alessandro
Zaninetti Piero
 Zanini Riccardo
 Zennaro Walter
Zingaro Angelo
 Zito Alfonso
 Zollino Luciana
 Zovi Maria Carla
 Zunino Roberto